Sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their ...

PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength ...

Pfizer's strength lies in its integrated approach to drug development, from discovery to clinical trials, and finally, ...

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent cliffs. Read more here.

Pfizer’s stock has dropped in the double digits over three years. The company faces declines in sales of its coronavirus products and the loss of exclusivity of other major products. But over the past ...

Pfizer on Tuesday reported its first quarterly loss since 2019 as demand for its COVID products dwindled. Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter ...

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its ...

Pfizer’s PFE top line has been declining in 2023 due to a steep drop in revenues from its COVID-19 products, the Comirnaty vaccine and Paxlovid oral pill, on lower demand due to the end of the ...

Drug giant Pfizer is informing hospitals that dozens of its products could face “continued or new supply disruptions in the near-term” after an EF-3 tornado last week severely damaged its plant in ...

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...